

# **Batten Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034**

<https://marketpublishers.com/r/BA17539C7E56EN.html>

Date: May 2024

Pages: 139

Price: US\$ 6,499.00 (Single User License)

ID: BA17539C7E56EN

## **Abstracts**

The 7 major Batten disease markets are expected to exhibit a CAGR of 5.55% during 2024-2034.

The Batten disease market has been comprehensively analyzed in IMARC's new report titled "Batten Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Batten disease, also known as neuronal ceroid lipofuscinosis, refers to a rare and progressive genetic disorder that primarily affects the nervous system. It is characterized by the accumulation of lipopigments, specifically ceroid and lipofuscin, in various tissues throughout the body, particularly in the nerve cells of the brain. Afflicting mainly children, it begins stealthily, often with subtle signs like vision problems, clumsiness, personality changes, etc. As the disease advances, affected individuals suffer from seizures, cognitive decline, as well as motor impairments, such as loss of coordination and muscle weakness. Vision deterioration persists, leading to blindness, and speech difficulties arise, making communication challenging. In its later stages, Batten disease ravages the nervous system, causing severe dementia, complete loss of motor function, and, ultimately, a shortened life expectancy. The diagnostic process often involves a combination of clinical evaluation, genetic testing, neuroimaging studies to check seizure activity, visual assessment, and biochemical analysis of blood and urine samples to detect biomarkers associated with the ailment. Neuropsychological assessments are also crucial in evaluating cognitive function. Besides this, genetic testing, including next-generation sequencing, plays a central role in confirming the diagnosis by identifying pathogenic variants in genes associated with Batten disease.

The rising cases of mutations in various genes responsible for the production of

enzymes involved in lysosomal function are primarily driving the Batten disease market. Besides this, the increasing utilization of electroencephalography (EEG) for assessing and characterizing seizures in patients is also augmenting the market growth. Specific EEG patterns, such as slow waves and epileptiform discharges, can aid in differentiating the ailment from other epileptic conditions. Furthermore, the widespread adoption of chaperone therapy, which aims to develop small molecules that can stabilize misfolded proteins and improve their function, thereby potentially slowing disease progression, is creating a positive outlook for the market. Additionally, several key players are making extensive investments in R&D activities to introduce drugs that enhance lysosomal function, reduce neuroinflammation, promote neuroprotection, and modify disease-related pathways. This, in turn, is further acting as another significant growth-inducing factor. Moreover, the emerging popularity of autophagy modulation, since it promotes the removal of damaged proteins and organelles, thereby reducing cellular stress as well as promoting neuronal health, is expected to drive the Batten disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Batten disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Batten disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Batten disease market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany  
France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the Batten disease market  
Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the Batten disease market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Batten disease marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

## Key Questions Answered in this Report: Market Insights

How has the Batten disease market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the Batten disease market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Batten disease market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Batten disease across the seven major markets?

What is the number of prevalent cases (2018-2034) of Batten disease by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of Batten disease by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of Batten disease by type across the seven major markets?

How many patients are diagnosed (2018-2034) with Batten disease across the seven major markets?

What is the size of the Batten disease patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of Batten disease?

What will be the growth rate of patients across the seven major markets?

## Batten Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Batten disease drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Batten disease market?

What are the key regulatory events related to the Batten disease market?

What is the structure of clinical trial landscape by status related to the Batten disease market?

What is the structure of clinical trial landscape by phase related to the Batten disease market?

What is the structure of clinical trial landscape by route of administration related to the Batten disease market?

## Contents

?1 Preface

### **2 SCOPE AND METHODOLOGY**

2.1 Objectives of the Study

2.2 Stakeholders

2.3 Data Sources

2.3.1 Primary Sources

2.3.2 Secondary Sources

2.4 Market Estimation

2.4.1 Bottom-Up Approach

2.4.2 Top-Down Approach

2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 BATTEN DISEASE - INTRODUCTION**

4.1 Overview

4.2 Regulatory Process

4.3 Epidemiology (2018-2023) and Forecast (2024-2034)

4.4 Market Overview (2018-2023) and Forecast (2024-2034)

4.5 Competitive Intelligence

### **5 BATTEN DISEASE - DISEASE OVERVIEW**

5.1 Introduction

5.2 Symptoms and Diagnosis

5.3 Pathophysiology

5.4 Causes and Risk Factors

5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 BATTEN DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION**

7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Epidemiology by Type (2018-2034)
  - 7.2.6 Diagnosed Cases (2018-2034)
  - 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Epidemiology by Type (2018-2034)
  - 7.3.6 Diagnosed Cases (2018-2034)
  - 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Epidemiology by Type (2018-2034)
  - 7.4.6 Diagnosed Cases (2018-2034)
  - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Epidemiology by Type (2018-2034)
  - 7.5.6 Diagnosed Cases (2018-2034)
  - 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Epidemiology by Type (2018-2034)
  - 7.6.6 Diagnosed Cases (2018-2034)

- 7.6.7 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)
  - 7.7.4 Epidemiology by Gender (2018-2034)
  - 7.7.5 Epidemiology by Type (2018-2034)
  - 7.7.6 Diagnosed Cases (2018-2034)
  - 7.7.7 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Epidemiology by Type (2018-2034)
  - 7.8.6 Diagnosed Cases (2018-2034)
  - 7.8.7 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Epidemiology by Type (2018-2034)
  - 7.9.6 Diagnosed Cases (2018-2034)
  - 7.9.7 Patient Pool/Treated Cases (2018-2034)

## **8 BATTEN DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 BATTEN DISEASE - UNMET NEEDS**

## **10 BATTEN DISEASE - KEY ENDPOINTS OF TREATMENT**

## **11 BATTEN DISEASE - MARKETED PRODUCTS**

- 11.1 List of Batten Disease Marketed Drugs Across the Top 7 Markets



### 11.1.1 Brineura (Cerliponase alfa) - BioMarin Pharmaceutical

- 11.1.1.1 Drug Overview
- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 BATTEN DISEASE - PIPELINE DRUGS**

### 12.1 List of Batten Disease Pipeline Drugs Across the Top 7 Markets

#### 12.1.1 AT GTX 502 - Amicus Therapeutics

- 12.1.1.1 Drug Overview
- 12.1.1.2 Mechanism of Action
- 12.1.1.3 Clinical Trial Results
- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status

#### 12.1.2 NGN101 - Neurogene Inc

- 12.1.2.1 Drug Overview
- 12.1.2.2 Mechanism of Action
- 12.1.2.3 Clinical Trial Results
- 12.1.2.4 Safety and Efficacy
- 12.1.2.5 Regulatory Status

#### 12.1.3 RGX381 - REGENXBIO

- 12.1.3.1 Drug Overview
- 12.1.3.2 Mechanism of Action
- 12.1.3.3 Clinical Trial Results
- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

## **13. BATTEN DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14. BATTEN DISEASE – CLINICAL TRIAL LANDSCAPE**

### 14.1 Drugs by Status

- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 BATTEN DISEASE - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Batten Disease - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Batten Disease - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Batten Disease - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Batten Disease - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034)
  - 15.3.3 Batten Disease - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Batten Disease - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Batten Disease - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Batten Disease - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Batten Disease - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Batten Disease - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Batten Disease - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom

- 15.6.1 Batten Disease - Market Size
  - 15.6.1.1 Market Size (2018-2023)
  - 15.6.1.2 Market Forecast (2024-2034)
- 15.6.2 Batten Disease - Market Size by Therapies
  - 15.6.2.1 Market Size by Therapies (2018-2023)
  - 15.6.2.2 Market Forecast by Therapies (2024-2034)
- 15.6.3 Batten Disease - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Batten Disease - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Batten Disease - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Batten Disease - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Batten Disease - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Batten Disease - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Batten Disease - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Batten Disease - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Batten Disease - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Batten Disease - Access and Reimbursement Overview

## **16 BATTEN DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 BATTEN DISEASE MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses

17.3 Opportunities

17.4 Threats

## **18 BATTEN DISEASE MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Batten Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/BA17539C7E56EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BA17539C7E56EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

